Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters? - Takeaways - MDSpire

Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters?

  • By

  • Cecilia Lina Pugliano

  • Raymond Fueng-Hin Liang

  • Andrea Ruffa

  • Marietta Iacucci

  • Subrata Ghosh

  • August 1, 2025

  • 0 min

Share

  • 1

    Monoclonal antibodies targeting IL-23p19, including Risankizumab, Mirikizumab, and Guselkumab, are effective for treating moderate-to-severe IBD.

  • 2

    Key factors in selecting an anti-IL23p19 agent include patient preference, IBD phenotype, and presence of coexisting conditions.

  • 3

    Guselkumab is notable for its unique ability to bind CD64, potentially enhancing therapeutic effects in IBD.

  • 4

    The introduction of subcutaneous induction therapy with Guselkumab offers a viable alternative to intravenous administration.

  • 5

    Further real-world studies are necessary to evaluate the effectiveness of anti-IL23p19 therapies in complex IBD phenotypes.

Original Source(s)

Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters?

  • by Cecilia Lina Pugliano, Raymond Fueng-Hin Liang, Andrea Ruffa, Marietta Iacucci, Subrata Ghosh

  • August 1, 2025

Related Content

Genes Predict Bowel Disease Severity

Large study suggests genetic risk scores could help doctors identify patients who need closer monitoring and earlier treatment

  • March 12, 2026

  • 2 min
AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.

Rapunzel Syndrome Masks Weight Loss

Researchers identify an extensive trichobezoar in a child with progressive weight loss and feeding changes.